None listed
Conditions
Brief summary
The primary aim of this study is to evaluate the effect of a titrated respiratory physiotherapy treatment protocol on subject quality of life over a 12-month period. Secondary outcomes include rate of lung infections (pulmonary exacerbations), spirometry, patient self-efficacy and the patient experience assessed through qualitative interviewing. Enrolled study participants will be provided a tailored airway clearance program by a trained respiratory physiotherapist to augment clearance of excess secretions from the lungs. The efficacy of this program will be reviewed at regular intervals during the treatment period. If required the subject’s airway clearance regime will be up-titrated to improve effectiveness of the treatment. We hypothesise that this outcome-based customization of airway clearance will improve quality of life, spirometry and self-efficacy in patients with bronchiectasis.
Interventions
The effect of usual care will be studied in patients receiving respiratory physiotherapy for the treatment of bronchiectasis.
Participants will be monitored at month 1, 3 and 12 with a review of quality of life, spirometry, exacerbation frequency and self efficacy.
Usual care consists of a a diverse range of physiotherapy treatments (such as education, positive expiratory pressure therapy, oscillating positive expiratory Pressure therapy, gravity assisted drainage and nebulised saline adjunc
The effect of usual care will be studied in patients receiving respiratory physiotherapy for the treatment of bronchiectasis. Participants will be monitored at month 1, 3 and 12 with a review of quality of life, spirometry, exacerbation frequency and self efficacy. Usual care consists of a a diverse range of physiotherapy treatments (such as education, positive expiratory pressure therapy, oscillating positive expiratory Pressure therapy, gravity assisted drainage and nebulised saline adjuncts) used to optimise airway clearance in bronchiectasis patients that will be administered in an as needed basis, titrating therapies to individual needs. Participants who choose not to enroll or are ineligible for the study will continue to receive usual care treatment at the practice (same therapy as the study protocol) Completion of the questionnaires will take approximately 15 minutes per session. A baseline spirometry will usually take an addition 15 minutes to complete. All assessments (spirometry inclusive) will be performed by the treating physiotherapist. A spirometry assessment involves a maximal inhale, followed by a maximal forced exhale into a calibrated device which measures the volume and flow of air expired.
Sponsors
The University of Sydney
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1) Provide their informed consent to participate. 2) Male or Female above 18 years of age (inclusive) at screening. 3) Bronchiectasis diagnosed by a treating physician.
Exclusion criteria
1) Current smokers as defined by the Centre of Disease C ontrol. 2) Inability to follow the procedures of the study (e.g. due to barriers of language or cognition) 3) Cardiothoracic surgery within 6 weeks prior to enrolment 4) Subjects who have had adjustments to their baseline medications within 1 month prior to screening 5) Subjects who started on macrolides within 12 months of enrolment. 6) Subjects taking antibiotics for an acute exacerbation at the time of enrolment. 7) Severe concomitant illness that may prevent optimal participation in the study 8) A direct relative of the investigation team 9) Women who are pregnant 10) Participation in another clinical trial for bronchiectasis
Outcome results
None listed